The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle
- PMID: 1281322
- DOI: 10.1002/pros.2990210406
The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle
Abstract
The objective of the present study was to determine whether the smooth muscle content of the prostate adenoma is related to the clinical response to terazosin, a long-acting selective alpha 1 blocker. Multiple random biopsies of the prostate were obtained from 26 male subjects with symptomatic benign prostatic hyperplasia (BPH) prior to initiating therapy with terazosin. Double immunoenzymatic staining and computer-assisted quantitative color image analysis were utilized to quantify the area density of smooth muscle, connective tissue, glandular epithelium, and glandular lumen. The clinical response to alpha blockade was based upon changes in peak urinary flow rate and the Boyarsky symptom score. A significant direct relationship was observed between the percent area density of smooth muscle and the percent change in peak urinary flow rate. A statistically significant correlation between the percent area density of smooth muscle and the percent change in Boyarsky symptom score was not observed. The percent area density of prostate smooth muscle in the subjects exhibiting a favorable clinical response was 38% greater than the nonresponders (P = 0.068). The clinical response to alpha blockade in BPH is related to the area density of prostate smooth muscle.
Similar articles
-
[Relationship between the quantitative morphometry and the clinical response to alpha adrenergic blocker in benign prostatic hyperplasia].Nihon Hinyokika Gakkai Zasshi. 1996 Mar;87(3):695-701. doi: 10.5980/jpnjurol1989.87.695. Nihon Hinyokika Gakkai Zasshi. 1996. PMID: 8709447 Clinical Trial. Japanese.
-
Terazosin in the treatment of benign prostatic hyperplasia: the United States experience.Br J Urol. 1992 Nov;70 Suppl 1:2-9. doi: 10.1111/j.1464-410x.1992.tb15860.x. Br J Urol. 1992. PMID: 1281728 Review.
-
Effect of terazosin on clinical benign prostatic hyperplasia in older adults.J Am Geriatr Soc. 2003 Mar;51(3):424-6. doi: 10.1046/j.1532-5415.2003.51120.x. J Am Geriatr Soc. 2003. PMID: 12588590
-
Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia.Int J Urol. 2001 Feb;8(2):42-8. doi: 10.1046/j.1442-2042.2001.00243.x. Int J Urol. 2001. PMID: 11240824
-
Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.Pharmacoeconomics. 1997 Feb;11(2):184-97. doi: 10.2165/00019053-199711020-00008. Pharmacoeconomics. 1997. PMID: 10165827 Review.
Cited by
-
The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.Curr Urol Rep. 2003 Aug;4(4):276-81. doi: 10.1007/s11934-003-0084-1. Curr Urol Rep. 2003. PMID: 12882718 Review. No abstract available.
-
Conservative non-instrumental treatment of benign prostatic hyperplasia.Urol Res. 1997;25 Suppl 2:S107-14. doi: 10.1007/BF00941996. Urol Res. 1997. PMID: 9144895 Review.
-
Pathophysiology of lower urinary tract symptoms in the aging male population.Rev Urol. 2005;7 Suppl 7(Suppl 7):S3-S11. Rev Urol. 2005. PMID: 16986059 Free PMC article.
-
Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease.Rev Urol. 2009 Fall;11(Suppl 1):S9-S13. Rev Urol. 2009. PMID: 20126609 Free PMC article.
-
PSA density is associated with BPH cellular composition.Prostate. 2022 Sep;82(12):1162-1169. doi: 10.1002/pros.24367. Epub 2022 Jun 2. Prostate. 2022. PMID: 35652548 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical